二甲双胍用于开始雄激素剥夺治疗的转移性前列腺癌患者:STAMPEDE平台方案随机3期试验
STAMPEDE平台随机3期试验纳入1874例转移性激素敏感性前列腺癌患者,1:1随机接受标准治疗或标准治疗联合二甲双胍850mg每日两次。中位随访60个月,二甲双胍组中位生存67.4个月 vs 标准治疗组61.8个月(HR 0.91,95%CI 0.80-1.03;p=0.15),无显著总生存获益。二甲双胍组3级及以上胃肠道不良事件更常见(9% vs 7%),但ADT相关代谢副作用显著减少。
要点
- 转移性激素敏感性前列腺癌中,标准治疗联合二甲双胍未显著改善总生存(HR 0.91,95%CI 0.80-1.03;p=0.15)。
- 二甲双胍组3级及以上不良事件发生率57% vs 标准治疗组52%,胃肠道3级及以上不良事件9% vs 7%。
- 二甲双胍组ADT相关代谢副作用较标准治疗组显著减少。
核心结论
- 在转移性激素敏感性前列腺癌总体人群中,标准治疗联合二甲双胍未发现显著的总生存获益。
- 二甲双胍副作用谱与预期一致,主要为腹泻。
- 二甲双胍组ADT相关代谢副作用较标准治疗组显著减少。
研究设计与样本
- STAMPEDE多臂多阶段随机3期试验,招募经同位素骨扫描和CT扫描分期的局部晚期高危或转移性前列腺腺癌患者。
- 纳入非糖尿病(糖化血红蛋白<48 mmol/mol[相当于<6.5%])、肾功能充足(肾小球滤过率≥45 ml/min/1.73 m²)且WHO体能状态0-2分的转移性患者。
- 从英国和瑞士112家医院招募,1:1随机分配至标准治疗或标准治疗联合二甲双胍850 mg每日两次。
- 随机采用电话最小化法(含20%随机因素),按随机医院、年龄(<70岁 vs ≥70岁)、WHO体能状态(0 vs 1或2)、ADT类型、长期规律使用阿司匹林或非甾体抗炎药(是 vs 否)、盆腔淋巴结状态(阳性 vs 阴性)、计划放疗(是 vs 否)、计划多西他赛或雄激素受体通路抑制剂(多西他赛 vs 阿比特龙、恩扎卢胺或阿帕他胺 vs 无)分层。
- 标准治疗包括ADT联合或不联合放疗、联合或不联合多西他赛或ARPI;主要终点为意向治疗人群的总生存(任何原因死亡时间)。
主要发现
- 2016年9月5日至2023年3月31日,1874例转移性患者随机分配至标准治疗组(n=938)或标准治疗联合二甲双胍组(n=936)。
- 中位年龄69岁(IQR 63-73),中位PSA 84 ng/mL(24-352);1758例(94%)为新诊断转移性疾病,116例(6%)为异时性复发疾病。
- 1543例(82%)接受ADT联合多西他赛,52例(3%)接受阿比特龙、恩扎卢胺或阿帕他胺。
- 标准治疗组报告473例死亡,中位生存61.8个月(IQR 29.7至未达到);二甲双胍组报告453例死亡,中位生存67.4个月(32.5至未达到;HR 0.91,95%CI 0.80-1.03;p=0.15)。
- 标准治疗组487例(52%)报告3级及以上不良事件,标准治疗联合二甲双胍组523例(57%);胃肠道3级及以上不良事件分别为61例(7%)和84例(9%);标准治疗组6例药物相关死亡,二甲双胍组1例。
关键数值与推荐
- 主要终点总生存:标准治疗组中位61.8个月 vs 二甲双胍组67.4个月(HR 0.91,95%CI 0.80-1.03;p=0.15),未达统计学显著。
- 3级及以上不良事件:标准治疗组52%(487/938) vs 二甲双胍组57%(523/921)。
- 3级及以上胃肠道不良事件:标准治疗组7%(61/938) vs 二甲双胍组9%(84/921)。
- 药物相关死亡:标准治疗组6例 vs 二甲双胍组1例。
临床怎么用
- 原文结论认为在转移性激素敏感性前列腺癌总体人群中,标准治疗联合二甲双胍未显示显著总生存获益。
- 原文结论指出二甲双胍副作用谱与预期一致,主要为腹泻。
- 原文结论指出二甲双胍组ADT相关代谢副作用较标准治疗组显著减少。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metformin is a widely used anti-diabetic drug. Several studies have suggested that metformin has anticancer activity in some malignancies, including prostate cancer. Metformin might also mitigate the adverse metabolic effects of androgen-deprivation therapy (ADT). We hypothesised that metformin might improve survival in patients with metastatic hormone-sensitive prostate cancer and reduce metabolic complications associated with ADT. METHODS: The STAMPEDE multi-arm, multi-stage, randomised phase 3 trial recruited patients with high-risk locally advanced or metastatic adenocarcinoma of the prostate staged by conventional imaging with isotope bone and CT scanning. This publication reports findings for the most recent STAMPEDE research question, testing the addition of metformin to standard of care for non-diabetic (glycated haemoglobin [HbA1c] <48 mmol/mol [equivalent to <6·5%]) patients with metastatic disease with adequate renal function (glomerular filtration rate ≥45 ml/min/1·73 m2) and WHO performance status 0-2. This trial recruited from 112 hospitals in the UK and Switzerland to the STAMPEDE protocol. Patients were randomly allocated (1:1) to standard of care or standard of care plus metformin 850 mg twice daily. Random assignment was by telephone using minimisation with a random element of 20% (developed and maintained by the MRC Clinical Trials Unit at UCL), stratified for randomising hospital, age (<70 years vs ≥70 years), WHO performance status (0 vs 1 or 2), type of ADT, regular long-term use of aspirin or non-steroidal anti-inflammatory drugs (NSAIDs; yes vs no), pelvic nodal status (positive vs negative), planned radiotherapy (yes vs no), and planned docetaxel or androgen receptor pathway inhibitor (ARPI) use (docetaxel vs abiraterone, enzalutamide, or apalutamide vs none). Standard of care comprised ADT with or without radiotherapy and with or without docetaxel or ARPI. The primary outcome measure was overall survival, defined as the time to death from any cause, assessed in the intention-to-treat population. Safety was assessed in patients who started treatment. The trial is registered with ClinicalTrials.gov, NCT00268476 and ISRCTN, ISRCTN78818544. FINDINGS: Between Sep 5, 2016, and Mar 31, 2023, 1874 patients with metastatic disease were randomly allocated to standard of care (n=938) or standard of care plus metformin (n=936). The median patient age was 69 years (IQR 63-73) and the median PSA was 84 ng/mL (24-352). 1758 (94%) of 1874 patients were newly diagnosed with metastatic disease and 116 (6%) were diagnosed with metachronous relapsing disease. 1543 (82%) of 1874 patients received ADT plus docetaxel and 52 (3%) received abiraterone, enzalutamide, or apalutamide. The median time to most recent case report form follow-up was 60 months (IQR 49-72). 473 deaths were reported in the standard of care group; median survival was 61·8 months (IQR 29·7 to not reached). There were 453 deaths in the metformin group; median survival was 67·4 months (32·5 to not reached; HR 0·91, 95% CI 0·80-1·03; p=0·15). Grade 3 or worse adverse events were reported in 487 (52%) of 938 patients in the standard of care group and 523 (57%) of 921 patients in the standard of care plus metformin group. 61 (7%) patients in the standard of care group and 84 (9%) patients in the standard of care plus metformin group reported at least one grade 3 or worse gastrointestinal adverse event; all other body systems showed no difference in grade 3 adverse events. There were six drug-related deaths in the standard of care group and one in the standard of care plus metformin group. INTERPRETATION: We did not find significant evidence of an overall survival benefit of adding metformin to standard of care in the overall population of patients with metastatic hormone-sensitive prostate cancer. The side-effect profile of metformin was as expected and consisted mainly of diarrhoea. Adverse metabolic side-effects of ADT were significantly reduced in the metformin group compared with the standard of care group. FUNDING: Cancer Research UK, Prostate Cancer UK, and UK Research and Innovation Medical Research Council.
引用
- Gillessen S, Murphy L, James ND, et al. Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol. Lancet Oncol. 2025. PMID: 40639383. doi:10.1016/S1470-2045(25)00231-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。